全文获取类型
收费全文 | 430篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 10篇 |
妇产科学 | 2篇 |
基础医学 | 54篇 |
口腔科学 | 3篇 |
临床医学 | 16篇 |
内科学 | 161篇 |
皮肤病学 | 9篇 |
神经病学 | 23篇 |
特种医学 | 33篇 |
外科学 | 29篇 |
预防医学 | 6篇 |
眼科学 | 3篇 |
药学 | 7篇 |
中国医学 | 2篇 |
肿瘤学 | 75篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 10篇 |
2020年 | 16篇 |
2019年 | 15篇 |
2018年 | 12篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 15篇 |
2014年 | 15篇 |
2013年 | 10篇 |
2012年 | 28篇 |
2011年 | 36篇 |
2010年 | 18篇 |
2009年 | 18篇 |
2008年 | 21篇 |
2007年 | 25篇 |
2006年 | 32篇 |
2005年 | 34篇 |
2004年 | 23篇 |
2003年 | 16篇 |
2002年 | 23篇 |
2001年 | 7篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 5篇 |
1995年 | 2篇 |
1993年 | 2篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1982年 | 1篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1970年 | 2篇 |
1931年 | 1篇 |
1929年 | 1篇 |
1928年 | 1篇 |
1922年 | 1篇 |
1921年 | 1篇 |
1903年 | 1篇 |
1897年 | 1篇 |
1895年 | 1篇 |
1894年 | 2篇 |
1893年 | 1篇 |
1892年 | 2篇 |
1861年 | 1篇 |
1860年 | 1篇 |
排序方式: 共有451条查询结果,搜索用时 0 毫秒
91.
Susanne Ghandili Cecilia Lindhauer Sven Pischke Julian Schulze zur Wiesch Philipp H. von Kroge Susanne Polywka Carsten Bokemeyer Walter Fiedler Nicolaus Krger Francis Ayuk Raissa Adjall Franziska Modemann 《Haematologica》2022,107(12):2870
Hepatitis E virus is increasingly being reported to cause chronic infection in immunocompromised patients. However, less is known about patients with an underlying hematologic disease. In particular, the impact of hepatitis E infection on oncological therapy has been poorly described. In this retrospective single-center study, we analyzed 35 hematologic patients with hepatitis E, including 20 patients under active oncological treatment and 15 patients who were in the post-treatment follow-up or under active surveillance. The primary aim was to describe the clinical courses with particular focus on any hepatitis E-related therapy modifications of cancer-directed therapy. In the majority (60%) of patients who were under active oncological treatment, hepatitis E-related therapy modifications were made, and 25% of deaths were due to progression of the hematologic disease. In patients receiving concomitant oncological treatment, no hepatitis E-related deaths occurred. In contrast, two patients in the follow-up group died from hepatitis E-associated acute-on-chronic liver failure. Chronic hepatitis E was observed in 34% of all cases and 43% received ribavirin therapy; of those, 27% achieved a sustained virological response. CD20-directed therapy was the only independent risk factor for developing chronic hepatitis E. We conclude that CD20-directed treatment at any time point is a risk factor for developing chronic hepatitis E. Nevertheless, since mortality from the progression of hematologic disease was higher than hepatitis E-related mortality, we suggest careful case-by-case decisions on modifications of cancer treatment. Patients in the post-treatment follow-up phase may also suffer from severe courses and hepatitis E chronicity occurs as frequently as in patients undergoing active therapy. 相似文献
92.
Lori Stolz Elaine Situ-LaCasse Josie Acuña Matthew Thompson Nicolaus Hawbaker Josephine Valenzuela Uwe Stolz Srikar Adhikari 《世界急诊医学杂志(英文)》2021,12(3):169
BACKGROUND: Traditionally performed using a subxiphoid approach, the increasing use of point-of-care ultrasound in the emergency department has made other approaches (parasternal and apical) for pericardiocentesis viable. The aim of this study is to identify the ideal approach for emergency-physician-performed ultrasound-guided pericardiocentesis as determined by ultrasound image quality, distance from surface to pericardial fluid, and likely obstructions or complications. 相似文献
93.
Nico Gagelmann Francesco Passamonti Christine Wolschke Radwan Massoud Christian Niederwieser Raissa Adjall Barbara Mora Francis Ayuk Nicolaus Krger 《Haematologica》2022,107(8):1840
Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an important preventive option against coronavirus disease 2019 (COVID-19), especially in fragile patients. We aimed to systematically analyze the outcomes of patients with hematological malignancies who received vaccination and to identify specific groups with differences in outcomes. The primary end point was antibody response after full vaccination (2 doses of mRNA or one dose of vector-based vaccines). We identified 49 studies comprising 11,086 individuals. Overall risk of bias was low. The pooled response for hematological malignancies was 64% (95% confidence interval [CI]: 59-69; I²=93%) versus 96% (95% CI: 92-97; I²=44%) for solid cancer and 98% (95% CI: 96-99; I²=55%) for healthy controls (P<0.001). Outcome was different across hematological malignancies (P<0.001). The pooled response was 50% (95% CI: 43-57; I²=84%) for chronic lymphocytic leukemia, 76% (95% CI: 67-83; I²=92%) for multiple myeloma, 83% (95% CI: 69-91; I²=85%) for myeloproliferative neoplasms, 91% (95% CI: 82-96; I²=12%) for Hodgkin lymphoma, and 58% (95% CI: 44-70; I²=84%) for aggressive and 61% (95% CI: 48-72; I²=85%) for indolent non-Hodgkin lymphoma. The pooled response for allogeneic and autologous hematopoietic cell transplantation was 82% and 83%, respectively. Being in remission and prior COVID-19 showed significantly higher responses. Low pooled response was identified for active treatment (35%), anti-CD20 therapy ≤1 year (15%), Bruton kinase inhibition (23%), venetoclax (26%), ruxolitinib (42%), and chimeric antigen receptor T-cell therapy (42%). Studies on timing, value of boosters, and long-term efficacy are needed. This study is registered with PROSPERO (clinicaltrials gov. Identifier: CRD42021279051). 相似文献
94.
Klaus Stelter Joachim Hiller John Martin Hempel Alexander Berghaus Hjalmar Hagedorn Michaela Andratschke Martin Canis 《European archives of oto-rhino-laryngology》2010,267(7):1129-1134
In previous studies, it was shown that the post-tonsillectomy wound infiltration of bupivacaine can reduce postoperative pain.
The objective of this study is to determine whether the postoperative wound infiltration with a mixture of bupivacaine, mepivacaine
and adrenaline is more effective than the sole application of bupivacaine. A prospective, double-blind, randomized, control
study included 30 patients scheduled for “cold steel” tonsillectomy. All patients obtained post-tonsillectomy infiltration
of 6.25 mg bupivacaine alone on one side and 3.75 mg bupivacaine, 25 mg mepivacaine and 0.0125 mg epinephrine on the other
side (intra-individual study design). Intake of analgesics and postoperative pain was assessed 0–6 days after surgery by visual
analogue scale in inactivity and during swallowing by the nurse staff. Bleeding, dysphagia, pain, aspiration or extraordinary
pain sensation were registered by the patient. The pain scores did not differ between the groups. All patients received systemic
painkillers; 6 (20%) patients needed intravenous analgesics. Postoperative haemorrhage occurred in two patients without correlation
to a certain local anaesthetic. Two patients developed sinus tachycardia for 2.5 min after epinephrine infiltration. Because
of cost-effectiveness and complication rates, we recommend only post-tonsillectomy wound infiltration of bupivacaine. The
injection should be placed in superficial muscle and connective tissue. A stringent systemic analgesia regime is indispensable
for pain relief after tonsillectomy. 相似文献
95.
Correlation of somatic mutations with outcome after FLAMSA‐busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes 下载免费PDF全文
Maximilian Christopeit Anita Badbaran Malik Alawi Tatjana Zabelina Gaby Zeck Christine Wolschke Francis Ayuk Nicolaus Kröger 《European journal of haematology》2016,97(3):288-296
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a curative treatment option for myelodysplastic syndromes (MDS). Little is known about the prognostic impact of mutations, for example, in TP53 specifically after allo‐HSCT. We here describe the prognostic impact of mutations in a panel of 19 genes analyzed by amplicon‐based next‐generation‐sequencing in a uniformly treated patient cohort. Sixty‐two patients with a median age of 61 yr suffered from MDS with 0–20% bone marrow blasts. International Prognostic Score was intermediate 1 (15%) and higher (79%). Conditioning uniformly was performed using a sequential approach in which FLAMSA chemotherapy was followed by Busulfan‐based conditioning. Patients mostly were transplanted from an unrelated donor (77%), and 36% of patients received a graft from a mismatched donor. Median number of mutations was 2 (range 0–6). RUNX1, GATA2, TET2, and CEBPA were the genes most frequently found mutated. TP53, a factor previously reported to confer adverse prognostic impact after allogeneic stem cell transplantation, was mutated in samples from eight patients, one of which showed a silent mutation. With an estimated 5‐yr overall/disease‐free survival of 48 ± 7%/41 ± 7%, none of the mutations analyzed showed a prognostic impact in this analysis of the largest uniformly treated cohort thus far. This especially holds true for patients with a mutation in TP53. 相似文献
96.
Yuewen Fu Thomas Schroeder Tatjana Zabelina Anita Badbaran Ulrike Bacher Guido Kobbe Francis Ayuk Christine Wolschke Susanne Schnittger Alexander Kohlmann Torsten Haferlach Nicolaus Kröger 《European journal of haematology》2014,92(3):189-194
Relapse is the major cause of treatment failure after allogeneic stem‐cell transplantation (AHSCT) for patients with myelodysplastic syndrome/myeloproliferative syndrome neoplasms (MDS/MPN). We evaluated the impact of molecular mutations on outcome and the value of molecular monitoring post‐transplantation. We screened 45 patients with chronic myelomonocytic leukemia (n = 39 patients, including seven with transformed‐acute myeloid leukemia), MDS/MPN unclassifiable (n = 5), and atypical BCR‐ABL1‐negative CML (n = 1) for mutations in ASXL1, CBL, NRAS, and TET2 genes by molecular genetics including a sensitive next‐generation sequencing (NGS) technique. In 36 patients, sufficient DNA was available for molecular analyses. In particular, TET2 and CBL mutations were screened applying amplicon deep sequencing. In 89% of cases, at least one mutation could be detected: ASXL1: n = 18 (50%); CBL: n = 7 (19%); TET2: n = 15 (42%); and NRAS: n = 11 (32%). Survival after AHSCT at 5 yr was 46% (95% CI 28–64%) and was not influenced by any mutation. After a median of 6 months after AHSCT in 33% of the patients, one of the molecular markers was still detectable, resulting in a higher incidence of relapse than in patients with undetectable mutations (50% vs. 15%, P = 0.04). In conclusion, pretransplant molecular mutation analysis can help to detect biomarkers in patients with MPN/MDS, which may be subsequently used as minimal residual disease markers after AHSCT. 相似文献
97.
Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results. 总被引:3,自引:0,他引:3
Gregg W Stone Antonio Colombo Paul S Teirstein Jeffrey W Moses Martin B Leon Nicolaus J Reifart Gary S Mintz Angela Hoye David A Cox Donald S Baim Bradley H Strauss Matthew Selmon Issam Moussa Takahiko Suzuki Hideo Tamai Osamu Katoh Kazuaki Mitsudo Eberhard Grube Louis A Cannon David E Kandzari Mark Reisman Robert S Schwartz Steven Bailey George Dangas Roxana Mehran Alexander Abizaid Patrick W Serruys 《Catheterization and cardiovascular interventions》2005,66(2):217-236
98.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma 总被引:11,自引:8,他引:11
Kröger N Schwerdtfeger R Kiehl M Sayer HG Renges H Zabelina T Fehse B Tögel F Wittkowsky G Kuse R Zander AR 《Blood》2002,100(3):755-760
We evaluated toxicity, engraftment, chimerism, graft-versus-host disease (GVHD), and response to a dose-reduced allograft after cytoreductive autografting in 17 patients with advanced stage II/III multiple myeloma (MM). After autografting with melphalan (200 mg/m2) the patients received after a median interval of 119 days (range 60-210) a dose-reduced regimen consisting of fludarabine (180 mg/m2), melphalan (100 mg/m2), and antithymocyte globulin (3 x 10 mg/kg) followed by allografting from related (n = 7), mismatched related (n = 2), or unrelated (n = 8) donors to induce a graft-versus-myeloma effect. After dose-reduced allografting all patients became neutropenic (< 0.2 x 10(9)/L) for at least 8 days. All patients engrafted with a median time for leukocyte (> 1 x 10(9)/L) and platelet (> 20 x 10(9)/L) counts of 16 (range, 11-24) and 23 days (range, 12-43), respectively. Complete donor chimerism was detected after a median of 30 days (range, 19-38). Acute GVHD stage II occurred in 4 patients (25%) and grade III GVHD in 2 patients (13%). Chronic GVHD developed in 40% of the patients, but only 1 patient experienced extensive chronic GVHD requiring further immunosuppressive therapy. Two patients died of alveolar hemorrhage and pneumonia, resulting in a day 100 mortality rate of 11%. The rate of complete remission with negative immunofixation increased from 18% after autografting to 73% after allografting. After a median follow-up of 17 months after autologous and 13 months after allogeneic transplantation 13 patients are alive and 12 of them free of relapse or progression. The tandem auto-allotransplant protocol is highly active and provides rapid engraftment with complete donor chimerism and tolerable toxicity. 相似文献
99.
Ioanna Triviai Thomas Stübig Birte Niebuhr Kais Hussein Asterios Tsiftsoglou Boris Fehse Carol Stocking Nicolaus Kr?ger 《Haematologica》2015,100(6):768-779
Primary myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis, megakaryocyte atypia, extramedullary hematopoiesis, and transformation to acute myeloid leukemia. To date the stem cell that undergoes the spatial and temporal chain of events during the development of this disease has not been identified. Here we describe a CD133+ stem cell population that drives the pathogenesis of primary myelofibrosis. Patient-derived circulating CD133+ but not CD34+CD133− cells, with a variable burden for JAK2V617F mutation, had multipotent cloning capacity in vitro. CD133+ cells engrafted for up to 10 months in immunocompromised mice and differentiated into JAK2-V617F+ myeloid but not lymphoid progenitors. We observed the persistence of human, atypical JAK2-V617F+ megakaryocytes, the initiation of a prefibrotic state, bone marrow/splenic fibrosis and transition to acute myeloid leukemia. Leukemic cells arose from a subset of CD133+ cells harboring EZH2D265H but lacking a secondary JAK2V617F mutation, consistent with the hypothesis that deregulation of EZH2 activity drives clonal growth and increases the risk of acute myeloid leukemia. This is the first characterization of a patient-derived stem cell population that drives disease resembling both chronic and acute phases of primary myelofibrosis in mice. These results reveal the importance of the CD133 antigen in deciphering the neoplastic clone in primary myelofibrosis and indicate a new therapeutic target for myeloproliferative neoplasms. 相似文献
100.
Tarah J. Ballinger Bipin N. Savani Vikas Gupta Nicolaus Kroger Mohamad Mohty 《European journal of haematology》2015,94(2):115-119
Hematopoietic stem cell transplantation (HCT) is currently the only curative treatment for myelofibrosis (MF), but this option is complicated by high incidences of associated morbidity and mortality. Ruxolitinib, a janus‐activated kinase (JAK) 1/2 inhibitor, has proven to be beneficial in reduction of splenomegaly, improvement of constitutional symptoms, and possibly in overall survival. However, use of JAK inhibitors in the peritransplant period has been complicated by unpredictable response, return of MF symptoms or cytokine storm reaction upon discontinuation, and lack of long‐term response data. This review considers the current limited available data on JAK inhibitor use prior to HCT, including common side effects and possible impact of severe adverse events on discontinuation of the drug. We provide our experience and recommendations regarding use of JAK inhibition in patients undergoing HCT. Additional studies are needed to determine the optimal schedule of JAK inhibitors in the transplant protocols and their impact on engraftment, graft‐versus‐host disease, and survival. 相似文献